BioCorRx (BICX): NIDA-Funded BICX104 Long-Acting Naltrexone Implant Clinical Trials & Peer Valuation vs. INDV, ALKS, ATAI
BICX
BioCorRx Inc. (OTCQB: BICX), through its subsidiary BioCorRx Pharmaceuticals, is developing BICX104, a long-acting biodegradable subcutaneous naltrexone pellet implant engineered to address medication non-compliance in Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD). Notably, the development of BICX104 has been heavily underwritten by non-dilutive grant awards from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), validating the scientific rigor of its sustained-release pharmacokinetic profile.
While Alkermes' monthly Vivitrol injection generates hundreds of millions in annual revenue despite patient drop-off after 30 days, a single multi-month BICX104 implant directly targets the compliance gap at a $6.55 million OTCQB market capitalization.
Sector Peer Valuation & Catalyst Comparison
| Ticker | Company | Exchange | Market Cap | Primary Catalyst / Focus |
|---|---|---|---|---|
| BICX (Subject) | BioCorRx Inc. | OTCQB | $6.55M | Addiction Medicine, Naltrexone Implants (BICX104) & CNS Biotech (2026-09-04 8-K) |
| ALKS | Alkermes plc | Nasdaq | $4.6B | Vivitrol (monthly injectable naltrexone) for AUD/OUD |
| INDV | Indivior PLC | Nasdaq | $1.35B | Sublocade & OUD pharmacotherapy franchise |
| ATAI | atai Life Sciences N.V. | Nasdaq | $290M | Clinical-stage mental health & substance-use disorder therapeutics |
Verified SEC EDGAR Filing Metrics (BICX · CIK 0001443863)
| Form | Filing Date | Disclosure Scope | EDGAR Source |
|---|---|---|---|
| 8-K | 2026-09-04 | SEC Form 8-K (Items: 5.02) | View EDGAR Filing → |
| 10-Q | 2026-08-14 | SEC Form 10-Q | View EDGAR Filing → |
| 10-Q | 2026-05-15 | SEC Form 10-Q | View EDGAR Filing → |
| 8-K | 2026-04-02 | SEC Form 8-K (Items: 1.01,3.02,9.01) | View EDGAR Filing → |
| 10-K | 2026-03-31 | SEC Form 10-K | View EDGAR Filing → |
| 10-Q | 2025-11-14 | SEC Form 10-Q | View EDGAR Filing → |
| 10-Q | 2025-08-14 | SEC Form 10-Q | View EDGAR Filing → |
| 8-K | 2025-08-01 | SEC Form 8-K (Items: 1.01,3.02,9.01) | View EDGAR Filing → |
What Active Traders & Microcap Desks Are Watching Next
Biotech catalyst traders and healthcare family offices are monitoring FDA clinical progression and pharmacokinetic data for BICX104, additional NIH/NIDA grant milestones, and strategic partnering discussions.
Primary sources (SEC EDGAR)
BICX Form 8-K (2026-09-04): https://www.sec.gov/Archives/edgar/data/1443863/000147793226005416/bicx_8k.htmBICX Form 10-Q (2026-08-14): https://www.sec.gov/Archives/edgar/data/1443863/000147793226005041/bicx_10q.htmBICX Form 10-Q (2026-05-15): https://www.sec.gov/Archives/edgar/data/1443863/000147793226003159/bicx_10q.htmBICX Form 8-K (2026-04-02): https://www.sec.gov/Archives/edgar/data/1443863/000147793226001957/bicx_8k.htmSee the dilution and promotion flags before you see the pitch.
Each week: the micro and small-caps now showing dilution or paid-promotion signals, with the SEC filing behind every flag. No recommendations, no price targets.